—Five abstracts presented at the 2024 Neurocritical Care Society Annual Meeting demonstrated the clinical impact of the FDA-cleared Ceribell System and Ceribell's AI-powered ClarityTM algorithm— —Clarity remains first and only device FDA 510(k) cleared for the diagnosis of electrographic status epilepticus— SUNNYVALE, Calif. , Oct. 16, 2024 /PRNewswire/ -- Ceribell, Inc.
(Nasdaq: CBLL ), a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the presentation of data in five abstracts at the 2024 Neurocritical Care Society (NCS) Annual Meeting being held from October 14-17 in San Diego . The analyses—which include 937 point-of-care EEG cases and recordings—add to the growing body of evidence highlighting the potential of Ceribell's point-of-care EEG (the Ceribell System) and AI-powered algorithm (ClarityTM) to reduce hospital length of stay and improve functional outcomes* compared to conventional EEG. Aaron Struck , M.
D., assistant professor and director of University of Wisconsin Comprehensive Epilepsy Program and EEG Lab, presented two sub-analyses from the primary SAFER-EEG trial , a multicenter, retrospective study of adult patients monitored with EEG during a hospital stay. "These two sub-analyses reinforce the importance of early seizure detection and management in improving outcomes for critically ill patients," said Dr.
Struck, the principal invest.
